Ireland - English - HPRA (Health Products Regulatory Authority)

pco manufacturing ltd. - letrozole - film-coated tablet - 2.5 milligram(s) - aromatase inhibitors; letrozole

Ireland - English - HPRA (Health Products Regulatory Authority)

rowex ltd - letrozole - film-coated tablet - 2.5 milligram(s) - aromatase inhibitors; letrozole

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - letrozole, quantity: 2.5 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; colloidal anhydrous silica; sodium starch glycollate; maize starch; magnesium stearate; lactose monohydrate; titanium dioxide; macrogol 8000; hypromellose; triacetin; iron oxide yellow; iron oxide red; quinoline yellow aluminium lake; polydextrose - for the treatment of postmenopausal women with hormone receptor positive breast cancer. the safety and efficacy of neoadjuvant use of letrozole has not been established. letrozole is not indicated in hormone receptor negative disease.

Ireland - English - HPRA (Health Products Regulatory Authority)

novartis ireland limited - letrozole - film-coated tablet - 2.5 milligram(s) - aromatase inhibitors; letrozole

Ireland - English - HPRA (Health Products Regulatory Authority)

imed healthcare ltd. - letrozole - film-coated tablet - 2.5 milligram(s) - aromatase inhibitors; letrozole

Ireland - English - HPRA (Health Products Regulatory Authority)

rowa pharmaceuticals limited - letrozole - film-coated tablet - 2.5 milligram(s) - aromatase inhibitors; letrozole

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - letrozole, quantity: 2.5 mg - tablet, film coated - excipient ingredients: lactose monohydrate; magnesium stearate; maize starch; sodium starch glycollate type a; colloidal anhydrous silica; hypromellose; microcrystalline cellulose; titanium dioxide; purified talc; iron oxide yellow; macrogol 400 - indicated for the treatment of post menopausal women with hormone receptor positive breast cancer. . the safety and efficacy of neoadjuvant use of letrozole has not been established. letrozole is not indicated in hormone receptor negative disease.

Australia - English - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - letrozole, quantity: 2.5 mg - tablet, film coated - excipient ingredients: lactose monohydrate; sodium starch glycollate; microcrystalline cellulose; hypromellose; colloidal anhydrous silica; magnesium stearate; titanium dioxide; iron oxide yellow; macrogol 400 - for the treatment of postmenopausal women with hormone receptor positive breast cancer (see clinical trials). the safety and efficacy of neoadjuvant use of letrozole has not been established. letrozole is not indicated in hormone receptor negative disease.

Malta - English - Medicines Authority

galenicum health, s.l.u calle sant gabriel, 50 esplugues de llobregat 08950 barcelona, spain - film-coated tablet - letrozole 2.5 mg - endocrine therapy

Malta - English - Medicines Authority

galenicum health, s.l.u calle sant gabriel, 50 esplugues de llobregat 08950 barcelona, spain - film-coated tablet - letrozole 2.5 mg - endocrine therapy